345 related articles for article (PubMed ID: 31515250)
1. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.
Yacoub A; Mascarenhas J; Kosiorek H; Prchal JT; Berenzon D; Baer MR; Ritchie E; Silver RT; Kessler C; Winton E; Finazzi MC; Rambaldi A; Vannucchi AM; Leibowitz D; Rondelli D; Arcasoy MO; Catchatourian R; Vadakara J; Rosti V; Hexner E; Kremyanskaya M; Sandy L; Tripodi J; Najfeld V; Farnoud N; Papaemmanuil E; Salama M; Singer-Weinberg R; Rampal R; Goldberg JD; Barbui T; Mesa R; Dueck AC; Hoffman R
Blood; 2019 Oct; 134(18):1498-1509. PubMed ID: 31515250
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Mascarenhas J; Kosiorek HE; Prchal JT; Rambaldi A; Berenzon D; Yacoub A; Harrison CN; McMullin MF; Vannucchi AM; Ewing J; O'Connell CL; Kiladjian JJ; Mead AJ; Winton EF; Leibowitz DS; De Stefano V; Arcasoy MO; Kessler CM; Catchatourian R; Rondelli D; Silver RT; Bacigalupo A; Nagler A; Kremyanskaya M; Levine MF; Arango Ossa JE; McGovern E; Sandy L; Salama ME; Najfeld V; Tripodi J; Farnoud N; Penson AV; Weinberg RS; Price L; Goldberg JD; Barbui T; Marchioli R; Tognoni G; Rampal RK; Mesa RA; Dueck AC; Hoffman R
Blood; 2022 May; 139(19):2931-2941. PubMed ID: 35007321
[TBL] [Abstract][Full Text] [Related]
3. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
Quintás-Cardama A; Kantarjian H; Manshouri T; Luthra R; Estrov Z; Pierce S; Richie MA; Borthakur G; Konopleva M; Cortes J; Verstovsek S
J Clin Oncol; 2009 Nov; 27(32):5418-24. PubMed ID: 19826111
[TBL] [Abstract][Full Text] [Related]
4. Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials.
Mazza GL; Mead-Harvey C; Mascarenhas J; Yacoub A; Kosiorek HE; Hoffman R; Dueck AC; Mesa RA;
Lancet Haematol; 2022 Jan; 9(1):e38-e48. PubMed ID: 34971581
[TBL] [Abstract][Full Text] [Related]
5. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
Melikyan AL; Subortseva IN; Gilyazitdinova EA; Koloshejnova TI; Pustovaya EI; Egorova EK; Kovrigina AM; Sudarikov AB; Abdullaev AO; Lomaia EG; Siordiya NT; Zaritskey AY; Savchenko VG
Ter Arkh; 2018 Aug; 90(7):23-29. PubMed ID: 30701919
[TBL] [Abstract][Full Text] [Related]
6. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.
Huang BT; Zeng QC; Zhao WH; Li BS; Chen RL
Leuk Res; 2014 Oct; 38(10):1177-83. PubMed ID: 25069759
[TBL] [Abstract][Full Text] [Related]
7. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.
Quintás-Cardama A; Abdel-Wahab O; Manshouri T; Kilpivaara O; Cortes J; Roupie AL; Zhang SJ; Harris D; Estrov Z; Kantarjian H; Levine RL; Verstovsek S
Blood; 2013 Aug; 122(6):893-901. PubMed ID: 23782935
[TBL] [Abstract][Full Text] [Related]
8. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial.
Masarova L; Patel KP; Newberry KJ; Cortes J; Borthakur G; Konopleva M; Estrov Z; Kantarjian H; Verstovsek S
Lancet Haematol; 2017 Apr; 4(4):e165-e175. PubMed ID: 28291640
[TBL] [Abstract][Full Text] [Related]
9. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
Gill H; Leung GMK; Yim R; Lee P; Pang HH; Ip HW; Leung RYY; Li J; Panagiotou G; Ma ESK; Kwong YL
Hematology; 2020 Dec; 25(1):247-257. PubMed ID: 32567517
[No Abstract] [Full Text] [Related]
10. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
Gisslinger H; Klade C; Georgiev P; Krochmalczyk D; Gercheva-Kyuchukova L; Egyed M; Rossiev V; Dulicek P; Illes A; Pylypenko H; Sivcheva L; Mayer J; Yablokova V; Krejcy K; Grohmann-Izay B; Hasselbalch HC; Kralovics R; Kiladjian JJ;
Lancet Haematol; 2020 Mar; 7(3):e196-e208. PubMed ID: 32014125
[TBL] [Abstract][Full Text] [Related]
11. Data-driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
Dam MJB; Pedersen RK; Knudsen TA; Andersen M; Skov V; Kjaer L; Hasselbalch HC; Ottesen JT
Eur J Haematol; 2021 Dec; 107(6):624-633. PubMed ID: 34411333
[TBL] [Abstract][Full Text] [Related]
12. Interferon apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis.
Zhang ZR; Duan YC
Asian Pac J Cancer Prev; 2014; 15(4):1681-4. PubMed ID: 24641389
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
Kiladjian JJ; Zachee P; Hino M; Pane F; Masszi T; Harrison CN; Mesa R; Miller CB; Passamonti F; Durrant S; Griesshammer M; Kirito K; Besses C; Moiraghi B; Rumi E; Rosti V; Blau IW; Francillard N; Dong T; Wroclawska M; Vannucchi AM; Verstovsek S
Lancet Haematol; 2020 Mar; 7(3):e226-e237. PubMed ID: 31982039
[TBL] [Abstract][Full Text] [Related]
14. Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia.
Kucine N; Bergmann S; Krichevsky S; Jones D; Rytting M; Jain J; Bennett CM; Resar LMS; Mascarenhas J; Verstovsek S; Hoffman R
Pediatr Blood Cancer; 2021 Mar; 68(3):e28888. PubMed ID: 33381905
[TBL] [Abstract][Full Text] [Related]
15. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R
Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
[TBL] [Abstract][Full Text] [Related]
16. Can pegylated interferon improve the outcome of polycythemia vera patients?
Crisà E; Cerrano M; Beggiato E; Benevolo G; Lanzarone G; Manzini PM; Borchiellini A; Riera L; Boccadoro M; Ferrero D
J Hematol Oncol; 2017 Jan; 10(1):15. PubMed ID: 28086927
[TBL] [Abstract][Full Text] [Related]
17. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha.
Stauffer Larsen T; Iversen KF; Hansen E; Mathiasen AB; Marcher C; Frederiksen M; Larsen H; Helleberg I; Riley CH; Bjerrum OW; Rønnov-Jessen D; Møller MB; de Stricker K; Vestergaard H; Hasselbalch HC
Leuk Res; 2013 Sep; 37(9):1041-5. PubMed ID: 23827351
[TBL] [Abstract][Full Text] [Related]
18. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
19. Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses.
Tashi T; Swierczek S; Kim SJ; Salama ME; Song J; Heikal N; King KY; Hickman K; Litton S; Prchal JT
Leukemia; 2018 Aug; 32(8):1830-1833. PubMed ID: 29556018
[No Abstract] [Full Text] [Related]
20. Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis.
Bewersdorf JP; Giri S; Wang R; Podoltsev N; Williams RT; Tallman MS; Rampal RK; Zeidan AM; Stahl M
Leukemia; 2021 Jun; 35(6):1643-1660. PubMed ID: 32868875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
